Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
information fournie par Boursorama CP 16/09/2021 à 08:30

- Initial Phase I data will be presented at ESMO Congress 2021 (poster presentation) starting today
- Clinical Proof of Concept for the feasibility of the intravenous administration of Transgene's patented oncolytic virus backbone behind the Invir.IO(TM) platform

Strasbourg, France, September 16, 2021, 8:30 am CEST - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the presentation of data from a Phase I study combining intravenous (IV) oncolytic virus TG6002 and oral 5-FC in patients with advanced gastrointestinal carcinomas at the European Society for Medical Oncology (ESMO) virtual meeting taking place from September 16-21, 2021.

.../...

Valeurs associées

TRANSGENE
0,8290 EUR Euronext Paris -0,72%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
CAC 40
8 006,73 +0,31%
Pétrole Brent
109,26 -1,50%
SOITEC
155 +8,28%
HAFFNER ENERGY
0,159 +14,72%
NOVACYT
0,663 -5,82%
Chargement...

Pages les plus populaires

L'offre BoursoBank